| Uppsala, Sweden, February 13, 2007
Gyros introduces new product for high concentration
protein quantification
Gyros announced today that it has extended its product range
with a new compact disc (CD) microlaboratory – Gyrolab Bioaffy®
20 HC – for dilution-free protein quantification in the grams
per liter range. |
| When quantifying proteins in high concentrations,
current technologies, such as ELISA, require extensive dilution
of samples in order to bring them into the technology’s measurable
range. This is cumbersome and time consuming for scientists and
increases the risk of quantification errors. By using very small
sample volumes and a high-capacity capture column, Gyrolab Bioaffy
20 HC increases the measurement range, allowing scientists to quantify
proteins in the grams per liter range without the need for any pre-assay,
sample dilution.
Both the new Gyrolab Bioaffy 20 HC and the existing Gyrolab Bioaffy
200 (for high sensitivity assays when detecting low concentrations)
CD microlaboratories are run on the same fully automated instrument,
Gyrolab® Workstation. As such, scientists are able to run a
diverse range of applications all using a single instrument. The
open design principle underlying the platform provides very wide
flexibility in the choice of target protein and allows experimental
set-up to be designed on a day-to-day basis.
|
|
An
example application where the introduction of Gyrolab Bioaffy 20
HC can greatly support the work of scientists is in process development
for the production of protein-based drugs (biopharmaceuticals),
such as monoclonal IgG. The combination of Gyrolab Bioaffy 20 HC
and Gyrolab Bioaffy 200 can be used to increase the efficiency of
biopharmaceutical process development by quickly and accurately
quantifying drug product and host cell proteins at concentrations
relevant for the entire purification process, from cell supernatant
to purified product.
Commenting on the launch, Jan Würtz, Gyros CEO, said, “The
new CD microlaboratory is an important addition to our product line
and extends the value of our offering to our growing customer base.
It also shows the versatility of our technology to meet different
application needs. Obviously, it strengthens our position for new
sales activity as well, and means that we can now offer a complete,
single system solution with an extremely broad measurement range
– something that is particularly well suited to biotherapeutic
applications.” |
About Gyros AB
Gyros is the leader in the miniaturization and integration of laboratory
applications through its proprietary microfluidics platform, Gyrolab
CD (compact disc) microlaboratory. Gyros delivers simple to use,
precisely controlled solutions for processing hundreds of samples
in parallel, generating more information from less sample and improving
lab productivity and efficiency.
Application-specific microlaboratories use a modular design offering
the potential to run different applications on a single instrument
and to create customized solutions. The company is currently focused
on two market segments: quantitative protein analysis for research,
drug discovery and development applications; and, in vitro diagnostics
for medical applications. Gyros has 50 employees working at its
headquarters and European sales office in Uppsala, Sweden and its
sales office in the USA.
For further information, visit www.gyros.com
or contact:
Jan Würtz, President and CEO, Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
jan.wurtz@gyros.com
Christina Burtsoff Asp, VP Marketing, Gyros AB
Tel: +46 (0)18 566 404
Mobile: +46 (0)70 666 1642
christina.asp@gyros.com
------------------------------------------------------------------------------------------------
Statements in this press release that are not strictly historical
may be forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be
duly noted that a variety of factors could cause actual results
and experiences to differ materially from what is herein expressed.
Risks and uncertainties include, but are not limited to, risks associated
with the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully develop,
adapt, produce or commercialize products, the ability to identify
and develop new products and to differentiate products from those
of competitors, as well as various legal hazards.
------------------------------------------------------------------------------------------------
|
